GLP-1 drugs have been around for more than two decades, having first been introduced in the US as a treatment for diabetes.
But since the beginning of the 2020s, after patients noted how much the medications suppressed their appetites – they have been relicensed and rebranded for use as weight loss drugs, with obese and overweight people injecting them either daily or weekly.
Wegovy, Ozempic, Zepbound and Mounjaro have gone from relative obscurity to household names, with at least 1.6million Britons using the jabs today.
And another shift is coming. Last week it was confirmed that the Wegovy Pill – an oral, once-daily version of the injectable Wegovy
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
